Compare · CDNA vs HUM
CDNA vs HUM
Side-by-side comparison of CareDx Inc. (CDNA) and Humana Inc. (HUM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CDNA and HUM operate in Medical Specialities (Health Care), so they compete in similar markets.
- HUM is the larger of the two at $51.90B, about 15.0x CDNA ($3.45B).
- HUM has been more active in the news (13 items in the past 4 weeks vs 6 for CDNA).
- HUM has more recent analyst coverage (25 ratings vs 20 for CDNA).
- Company
- CareDx Inc.
- Humana Inc.
- Price
- -
- -
- Market cap
- $3.45B
- $51.90B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- 2014
- News (4w)
- 6
- 13
- Recent ratings
- 20
- 25
CareDx Inc.
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It offers AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; and AlloSure Heart, a dd-cfDNA test to identify underlying cell injury leading to organ rejection. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; Olerup SBT, a product range for sequence-based typing of HLA alleles; QTYPE that enables precision in HLA typing at a low to intermediate resolution for samples that uses real-time polymerase chain reaction methodology; and TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Ottr, a transplant patient tracking software; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors. CareDx, Inc. has a license agreement with Illumina, Inc. for the distribution, development and commercialization rights to NGS products and technologies; and Cibiltech SAS to commercialize KidneyCare iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. CareDx, Inc. was incorporated in 1998 and is headquartered in South San Francisco, California.
Humana Inc.
Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. It operates through Retail, Group and Specialty, and Healthcare Services segments. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health benefits; and administrative services only products to individuals and employer groups, as well as military services, such as TRICARE T2017 East Region contract. Further, it offers pharmacy solutions, provider services, predictive modeling and informatics services, and clinical care services, such as home health and other services to its health plan members, as well as to third parties. As of December 31, 2020, the company had approximately 17 million members in medical benefit plans, as well as approximately 5 million members in specialty products. Humana Inc. was incorporated in 1964 and is headquartered in Louisville, Kentucky.
Latest CDNA
- CareDx to Report Third Quarter 2026 Financial Results on October 29, 2026
- SEC Form 4 filed by CareDx Inc.
- SEC Form 4 filed by CareDx Inc.
- SEC Form 4 filed by CareDx Inc.
- SEC Form 4 filed by CareDx Inc.
- SEC Form 4 filed by CareDx Inc.
- Amendment: CareDx Inc. filed SEC Form 8-K: Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets
- CFO & COO Kennedy Keith covered exercise/tax liability with 8,220 shares, decreasing direct ownership by 4% to 211,704 units (SEC Form 4) to satisfy withholding obligation
- Chief Commercial Officer Meng Jessica covered exercise/tax liability with 6,688 shares, decreasing direct ownership by 4% to 161,599 units (SEC Form 4) (for tax liability)
- Canaccord Genuity initiated coverage on CareDx with a new price target
Latest HUM
- Humana Announces New Strategic Joint Venture with BlackRock to Manage CenterWell Senior Primary Care Clinics
- SEC Form 8-K filed by Humana Inc.
- Humana Inc. to Release Third Quarter 2026 Results on November 6, 2026
- Humana upgraded by Raymond James with a new price target
- After a Record-Setting Week, Wall Street Turns to Inflation Data and the First Big Earnings Reports
- Humana upgraded by Robert W. Baird with a new price target
- Humana Announces Improved CMS Star Ratings with 95 Percent of Medicare Advantage Members in 4-Star or Above Plans for 2027
- SEC Form 8-K filed by Humana Inc.
- Humana upgraded by Cantor Fitzgerald with a new price target
- Humana Generates Nearly $20 Billion in Economic Impact Across Kentucky, New Report Finds